
Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.
Check out LLY stock price here.